ROCHELLE NAZARIAN: Open Payments
NPI 1417986860 · DANVERS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,562 in 107 payments from 26 companies in 2025. Trend: 2023 $7,468 · 2024 $7,722 · 2025 $3,562
Food & beverage: $3,550Education: $12
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $944 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $423 |
| Vanda Pharmaceuticals Inc. | 5 | $304 |
| ABBVIE INC. | 15 | $279 |
| Otsuka America Pharmaceutical, Inc. | 8 | $256 |
| Amgen Inc. | 7 | $224 |
| Viatris Specialty LLC | 5 | $199 |
| Lilly USA, LLC | 7 | $178 |
| PFIZER INC. | 7 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $108 |
Products named: CAPLYTA, BREZTRI, FARXIGA, FANAPT, REXULTI, EVENITY, YUPELRI, AIRSUPRA.
Industry payments across MA — which companies pay providers there.
